IREN Reports Q1 FY26 Results

IREN Reports Q1 FY26 Results GlobeNewswire November 06, 2025 Secured $9.7bn AI Cloud Contract with Microsoft Targeting $3.4bn AI Cloud ARR by End of 2026, Expansion to 140k GPUs 1 NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) — IREN Limited (NASDAQ: IREN) (“IREN” or “the Company”) today reported its financial results for the three months […]

IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights

IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights GlobeNewswire November 06, 2025 Presented new preclinical data on INB-619, a novel gamma-delta (γδ) T cell engager (TCE), demonstrating equivalent potency comparable to FDA-approved commercial products with minimal adverse cytokine release, highlighting its potential to achieve deep B cell depletion with an improved safety

Bimini Capital Management Announces Third Quarter 2025 Results

Bimini Capital Management Announces Third Quarter 2025 Results GlobeNewswire November 06, 2025 VERO BEACH, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) — Bimini Capital Management, Inc. (OTCQB: BMNM), (“Bimini Capital,” “Bimini,” or the “Company”), today announced results of operations for the three-month period ended September 30, 2025. Third Quarter 2025 Highlights Net income of approximately $1.8

BMO Insurance and Trupanion Join Forces to Bring Simple, Trusted Pet Insurance to More Canadians

BMO Insurance and Trupanion Join Forces to Bring Simple, Trusted Pet Insurance to More Canadians GlobeNewswire November 06, 2025 TORONTO, Nov. 06, 2025 (GLOBE NEWSWIRE) — BMO Insurance and Trupanion, the leading provider of medical insurance for cats and dogs in Canada, are partnering to expand access to trusted, high-quality pet health coverage for Canadian

Denali Therapeutics Announces Board and Executive Leadership Updates

Denali Therapeutics Announces Board and Executive Leadership Updates GlobeNewswire November 06, 2025 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (NASDAQ: DNLI) today announced updates to its Board of Directors and executive leadership team. Tim Van Hauwermeiren has been appointed to Denali's Board of Directors. Mr. Van Hauwermeiren is co-founder

Canoe EIT Income Fund Announces November 2025 Monthly Distribution and Quarterly Distribution on Preferred Units

Canoe EIT Income Fund Announces November 2025 Monthly Distribution and Quarterly Distribution on Preferred Units GlobeNewswire November 06, 2025 CALGARY, Alberta, Nov. 06, 2025 (GLOBE NEWSWIRE) — Canoe EIT Income Fund (the “Fund”) (TSX – EIT.UN) announces the November 2025 monthly distribution of $0.10 per unit. Additionally, the Fund announces a quarterly distribution for preferred

IPG Photonics Expands Operations to Huntsville Alabama, Bringing Innovation to the Defense Industry

IPG Photonics Expands Operations to Huntsville Alabama, Bringing Innovation to the Defense Industry GlobeNewswire November 06, 2025 MARLBOROUGH, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) — IPG Photonics today announced the grand opening of its new office and manufacturing facility in Huntsville, Alabama. This location in Redstone Gateway will be the headquarters of the newly created

ORIC(R) Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor

ORIC(R) Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor GlobeNewswire November 06, 2025 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of

Combined General Meeting of November 27, 2025 – Availability of the preparatory documents

Combined General Meeting of November 27, 2025 – Availability of the preparatory documents GlobeNewswire November 06, 2025 Daix (France), New York City (New York, United States), November 6, 2025 – Inventiva (Euronext Paris and Nasdaq : IVA) (“Inventiva” or the “Company“), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment

Statement of total voting rights and shares forming the company’s share capital as October 20, 2025

Statement of total voting rights and shares forming the company's share capital as October 20, 2025 GlobeNewswire November 06, 2025 Article R. 22-10-23 of the French Commercial Code Market : Euronext ParisISIN code / Mnemo : FR0013233012 / IVAWeb site : www.inventivapharma.com Date Number of Shares Outstanding Total voting rights, gross (1) Total voting rights,

Scroll to Top